AKT1 and ulcerative colitis: Existing study has shown that BA can significantly alleviate ulcerative colitis induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) by blocking the PI3K-AKT signaling pathway, thereby reducing the release of IL-6, TNF-α, and IL-1β (Zhu et al., 2020).